Effect of different doses of recombinant human growth hormone therapy on children with growth hormone deficiency: a retrospective observational study
Related Experiment Video
Updated: Jul 23, 2025
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
1Department of Children Healthcare, Anhui Children's Hospital, Hefei City, Anhui province, China. anan12192022@163.com.
Insights
Higher doses of recombinant human growth hormone (rhGH) significantly improve growth in children with growth hormone deficiency (GHD). This high-dose rhGH treatment is safe and effectively boosts growth factors for better development.
Area of Science:
- Pediatric Endocrinology
- Growth Hormone Therapy
- Child Development
Background:
- Growth hormone deficiency (GHD) affects children's growth and development.
- Recombinant human growth hormone (rhGH) is a standard treatment for GHD.
- Optimizing rhGH dosage is crucial for maximizing therapeutic outcomes.
Purpose of the Study:
- To compare the efficacy and safety of two different doses of rhGH in children with GHD.
- To evaluate the impact of low-dose (0.1 U/kg/d) versus high-dose (0.2 U/kg/d) rhGH on growth parameters.
- To assess biochemical and bone health markers following rhGH treatment.
Main Methods:
- Retrospective analysis of 136 GHD patients treated with rhGH for one year.
- Patients were divided into low-dose (70) and high-dose (66) groups.
- Collected data included height, weight, growth rate, bone age, bone density (SOS), IGF-1, IGFBP-3, GH levels, and adverse reactions.
Main Results:
- High-dose rhGH significantly increased height, weight, HtSDS, and growth rate compared to the low-dose group (p<0.05).
- Bone age increased in both groups, with a higher increase in the high-dose group. SOS decreased but was higher in the high-dose group.
- Serum levels of IGF-1, IGFBP-3, and GH were significantly elevated in the high-dose group (p<0.05).
- Adverse reaction incidence was similar between groups (8.6% vs. 6.1%, p>0.05).
Conclusions:
- High-dose rhGH (0.2 U/kg/d) is more effective than low-dose rhGH in promoting growth and development in children with GHD.
- The higher rhGH dosage safely upregulates key growth factors like IGF-1, IGFBP-3, and GH.
- This study supports the use of higher rhGH doses for enhanced therapeutic benefits in pediatric GHD.
Objective:
The aim of this study was to explore the effects of different doses of recombinant human growth hormone (rhGH) treatment on children with growth hormone deficiency (GHD).
Patients And Methods:
Medical records of 174 GHD patients admitted to our hospital from June 2019 to January 2022 were retrospectively evaluated. A total of 136 patients met the inclusion criteria, of which 70 received 0.1 U/ (kg·d) (low-dose group) and 66 received 0.2 U/ (kg·d) dose of rhGH treatment (high-dose group). Growth and development status [height, weight, height standard deviation (HtSDS), growth rate], bone age, bone density, speed of sound (SOS) as distal radius bone mass, biochemical indicators of growth and development [insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3)], growth hormone (GH) levels and incidence of adverse reactions were collected and compared between the two groups before and after one year of the treatment.
Results:
After the treatment, height, weight, HtSDS, and growth rate of the two groups increased compared to before the treatment and were significantly higher in the high-dose group than in the low-dose group (p<0.05). After one year of treatment, the following observations were made: the bone age of the two groups increased compared to the baseline values and was higher in the high-dose group compared to the low-dose group (p<0.05). The SOS of the two groups decreased but was significantly higher in the high-dose group compared to the low-dose group (p<0.05). Serum levels of IGF-1, IGFBP-3, and GH in both groups increased compared to the baseline values and were higher in the high-dose group than in the low-dose group (p<0.05). There was no significant difference in the incidence of adverse reactions between the high-dose group (8.6%) and the low-dose group (6.1%) (p>0.05).
Conclusions:
High-dose rhGH treatment for GHD is safe and can more effectively upregulate IGF-1, IGFBP-3, and GH, and promote the growth and development of children.
Related Concept Videos
01:10Nature and Nurture
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:28Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
01:21Factors Affecting Drug Response: Overview
01:22Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...